Cue Biopharma (CUE) vs Filana Therapeutics (FLNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cue Biopharma (CUE) has outperformed Filana Therapeutics (FLNA) over the past year, losing 76.8% versus a loss of 77.7%. Over five years, FLNA leads with a -98.9% price change compared with -98.9% for CUE. Cue Biopharma is the larger company by market cap ($34.7 million vs $32.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUE | FLNA |
|---|---|---|
| Share price | $4.15 | $0.6413 |
| Market cap | $34.69M | $32.26M |
| 1-day change | -7.78% | +14.52% |
| YTD return | -54.64% | -67.61% |
| 1-year return | -76.75% | -77.66% |
| 5-year return | -98.92% | -98.85% |
| EPS (TTM) | $-27.80 | $-0.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $27.47M | — |
| Revenue growth (YoY) | +195.75% | — |
| Net income (latest FY) | $-26.60M | $-90.97M |
| Operating margin | -96.67% | — |
| Net margin | -96.85% | — |
| 52-week high | $45.50 | $3.45 |
| 52-week low | $2.83 | $0.39 |
| Distance from 52-week high | -90.88% | -81.41% |
| Analyst consensus | none | none |
| Avg. price target upside | +2020.48% | +913.57% |
| Average volume | 567.02K | 2.09M |
| Shares outstanding | 8.36M | 50.30M |
| Employees | 29 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Filana Therapeutics
FLNA stock →Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
CUE vs FLNA FAQ
Which is bigger, Cue Biopharma or Filana Therapeutics?
Cue Biopharma (CUE) is larger, with a market capitalization of $34.69M compared with $32.26M for Filana Therapeutics (FLNA).
Which stock has performed better over the past year, CUE or FLNA?
CUE returned -76.75% over the past 12 months, compared with -77.66% for FLNA (price return, excluding dividends). Past performance does not predict future results.
Are Cue Biopharma and Filana Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.